Which factors are used to determine the treatment regimen for acute lymphoblastic leukemia (ALL)?

Updated: Oct 23, 2019
  • Author: Karen Seiter, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
  • Print


The treatment regimen for patients with ALL is determined primarily by the Philadelphia chromosome status of the leukemia and the age of the patient. Patients with Philadelphia chromosome–positive ALL receive a tyrosine kinase inhibitor (TKI) in combination with chemotherapy. Patients aged 15-39 years are referred to as "AYA" (adolescent and young adult) and are eligible for more intensive pediatric-style treatment regimens. Patients with Burkitt leukemia/lymphoma are treated with regimens specific for this diagnosis.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!